IMRIS, the US-based provider of interoperative magnetic resonance imaging (MRI) systems for use in operating theatres conducting advanced neurosurgery, has been acquired by private equity entity Grovecourt Capital Partners.
IMRIS provides the only movable MRI for use in hospitals and cancer centres that operates on a ceiling-mounted rail to glide between diagnostic and operating rooms to bring the MRI machine directly to the patient.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The provision means that patients can remain in a sterile surgical position for intraoperative imaging during neurosurgery and other use cases.
According to the MRI provider, the technology enhances surgical precision, reduces the need for follow-up procedures, and eliminates the requirement for post-surgical confirmatory MRI scans.
Grovecourt managing partner Matt Bergin stated that the private equity company was “thrilled” to partner with the IMRIS team to drive innovation, expand the company’s products and services, and enhance patient care.
The financial terms of the acquisition have not been disclosed.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIMRIS CEO Marc Buntaine commented: “Our partnership with Grovecourt marks a significant milestone for IMRIS.
“As the longstanding leader of intraoperative MRI systems for neurosurgery, we are eager to expand the boundaries of intraoperative MRI imaging into emerging applications, such as laser ablation and high-intensity focused ultrasound procedures.”
IMRIS joins Grovecourt’s growing portfolio of companies, including Miami-based teleradiology services provider, Premier Radiology Services, which it acquired in 2023.
According to GlobalData analysis, the combined global positron emission tomography (PET) and MRI systems market is growing at a CAGR of 10.40% and is forecast to reach a valuation of around $587m by 2033.
Elsewhere in the MRI space, US-based Prenuvo raised $120m earlier this month to finance the addition of modalities and analyses to its whole-body MRI screening platform. In addition, Philips recently announced a partnership with Myocardial Solutions to advance AI-driven cardiac MRI to improve early identification of heart disease in cancer patients and survivors.
